Program
23-valent pneumococcal capsular polysaccharide vaccine
Also written as “PPV23”, “23-valent pneumococcal polysaccharide vaccine” and “Pneumovax™ 23”.
Its studies are mostly in Pneumococcal Infections · Influenza, Human · Diphtheria · Pneumonia, Pneumococcal · Whooping Cough, led by 8 companies.
Drug page23-valent pneumococcal capsular polysaccharide vaccine: every studyMany companies study it; this page follows only the 16 they lead. All 39 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merckits history only | 50 open or running | phase 4since Oct 6, 2014 | Jul 3, 2007 | none ahead |
| GlaxoSmithKlineits history only | 40 open or running | phase 4since Feb 20, 2014 | Mar 24, 2006 | none ahead |
| Sinopharmits history only | 20 open or running | phase 4since Jan 6, 2021 | Jan 6, 2021 | none ahead |
| Aimei Vacin BioPharm (Zhejiang)its history only | 11 open or running | phase 3since Sep 13, 2023 | Sep 13, 2023 | none ahead |
| Chongqing Zhifei Biological Productsits history only | 10 open or running | phase 3since Feb 18, 2020 | Feb 18, 2020 | none ahead |
| Pfizerits history only | 10 open or running | phase 4since Aug 21, 2006 | Aug 21, 2006 | none ahead |
| Sanofiits history only | 10 open or running | phase 3since Dec 19, 2007 | Dec 19, 2007 | none ahead |
| Sinovac Biotechits history only | 10 open or running | phase 4since Jul 13, 2022 | Jul 13, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Mar 24, 2006.
- Aug 21, 2006Pfizer’s first study: phase 4 study in Pneumococcal InfectionsNew to PfizerPfizer · NCT00368186 · 51 enrolled · France
- Jul 3, 2007Merck’s first study: phase 3 study in Pneumococcal InfectionsNew to MerckMerck · NCT00496093 · 133 enrolled
- Sep 21, 2007Phase 3 study in Herpes ZosterMerck · NCT00535730 · 473 enrolled
- Dec 19, 2007Sanofi’s first study: phase 3 study in Streptococcus PneumoniaeNew to SanofiSanofi · NCT00594347 · 339 enrolled · Thailand
- Nov 21, 2012Phase 3 study in Pneumococcal InfectionsMerck · NCT01734239 · 102 enrolled
- Feb 20, 2014Phase 4 study in Whooping CoughGlaxoSmithKline · NCT02072525 · 359 enrolled · Canada
- Aug 14, 2014Phase 3 study in Influenza, HumanGlaxoSmithKline · NCT02218697 · 357 enrolled · Belgium, France
- Aug 22, 2014Phase 3 study in Pneumococcal InfectionsMerck · NCT02225587 · 400 enrolled
- Oct 6, 2014Phase 4 study in Pneumococcal InfectionsMerck · NCT02260882 · 243 enrolled
- Feb 9, 2020Phase 1 study in Healthy VolunteersGlaxoSmithKline · NCT04265911 · 126 enrolled · Japan
- Feb 18, 2020Chongqing Zhifei Biological Products’ first study: phase 3 study in Pneumonia, PneumococcalNew to Chongqing Zhifei Biological ProductsChongqing Zhifei Biological Products · NCT04278248 · 1,940 enrolled · China
- Jan 6, 2021Sinopharm’s first studies: 2 phase 4 studies in VaccinationNew to SinopharmSinopharm · NCT04701788, NCT04700618
- Jul 13, 2022Sinovac Biotech’s first study: phase 4 study in Influenza, HumanNew to Sinovac BiotechSinovac Biotech · NCT05471531 · 3,000 enrolled · China
- Sep 13, 2023Aimei Vacin BioPharm (Zhejiang)’s first study: phase 3 study in Pneumococcal InfectionsNew to Aimei Vacin BioPharm (Zhejiang)Aimei Vacin BioPharm (Zhejiang) · NCT06044077 · 1,920 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06044077Pneumococcal Infections · China | 3 | Recruiting | Aimei Vacin BioPharm (Zhejiang) | Mar 8, 2024 | 1,920 |
| NCT05471531Influenza, Human · China | 4 | Completed | Sinovac Biotech | Mar 10, 2022 | 3,000 |
| NCT04701788Vaccination · China | 4 | Completed | Sinopharm | Dec 20, 2021 | 331 |
| NCT04700618Vaccination · China | 4 | Completed | Sinopharm | Aug 22, 2021 | 330 |
| NCT04278248Pneumonia, Pneumococcal · China | 3 | Completed | Chongqing Zhifei Biological Products | Jun 7, 2018 | 1,940 |
| NCT04265911Healthy Volunteers · Japan | 1 | Completed | GlaxoSmithKline | Nov 7, 2020 | 126 |
| NCT02260882Pneumococcal Infections | 4 | Completed | Merck | Apr 9, 2015 | 243 |
| NCT02225587Pneumococcal Infections | 3 | Completed | Merck | Jul 6, 2015 | 400 |
| NCT02218697Influenza, Human · Belgium, France | 3 | Completed | GlaxoSmithKline | Jan 14, 2015 | 357 |
| NCT02072525Whooping Cough · Canada | 4 | Completed | GlaxoSmithKline | Jun 2, 2015 | 359 |
| NCT01734239Pneumococcal Infections | 3 | Completed | Merck | Oct 22, 2013 | 102 |
| NCT00594347Streptococcus Pneumoniae · Thailand | 3 | Completed | Sanofi | Mar 2008 | 339 |
| NCT00535730Herpes Zoster | 3 | Completed | Merck | Feb 2008 | 473 |
| NCT00496093Pneumococcal Infections | 3 | Completed | Merck | Jan 2006 | 133 |
| NCT00368186Pneumococcal Infections · France | 4 | Terminated | Pfizer | 51 | |
| NCT00307008Pneumonia · Sweden | 2 | Completed | GlaxoSmithKline | Feb 2005 | 1,198 |
How it is read
Names in the registry
- “PPV23”, 3 entries
- “23-valent pneumococcal polysaccharide vaccine”, 3 entries
- “Pneumovax™ 23”, 3 entries
- “Pneumo 23”, 2 entries
- “23-valent Pneumococcal Polysaccharide Vaccine (PPV23)”, 1 entry
Conditions, from the studies’ own filings
- Pneumococcal Infections, 6 studies
- Influenza, Human, 2 studies
- Diphtheria, 1 study
- Pneumonia, Pneumococcal, 1 study
- Whooping Cough, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.